In a small Phase 1 study, Viking’s once-daily oral VK 2735 led to dose-dependent reductions in weight with greatest weight loss — an average 6.8% at 28 days — achieved in the highest of the eight doses tested. The results were presented  during the ObesityWeek conference in San Antonio. Viking said   it plans to start a Phase II test of the tablet by the end of this year..

在一项小型的第一阶段研究中，维京人每天一次口服VK 2735可导致体重的剂量依赖性减轻，体重减轻程度最大（28天时平均为6.8%），在测试的八种剂量中最高。研究结果在圣安东尼奥举行的肥胖周会议上公布。。。

Viking designed VK 2735 to target and activate the GLP-1 and GIP receptors, the same receptors targeted by Eli Lilly’s injectable metabolic disorder drug tirzepatide, which is marketed as Zepbound for weight management. Viking has reached clinical testing with injectable and oral versions of its drug candidate..

Viking设计了VK 2735来靶向和激活GLP-1和GIP受体，这些受体与礼来公司的可注射代谢紊乱药物tirzepatide靶向的受体相同，该药物作为Zepbound用于体重管理。Viking已经通过其候选药物的注射和口服版本进行了临床测试。。

Recently, Viking reported preliminary Phase 1 data for oral VK 2735 showing an average placebo-adjusted weight loss of 3.3% after 28 days. In those results, the highest of the five doses tested was 40 mg. The latest results add data for 27 total patients — nine in each of three additional dose groups.

最近，Viking报告了口服VK 2735的初步第一阶段数据，显示28天后安慰剂调整后的平均体重减轻了3.3%。在这些结果中，测试的五个剂量中最高剂量为40毫克。最新结果增加了27名患者的数据，其中三个额外剂量组各有9名患者。

The average 6.8% weight reduction at 28 days was in the 100 mg cohort. Despite the higher doses in these cohorts, the study drug continued to be safe and well tolerated by patients. While gastrointestinal side effects are a known complication of currently available obesity meds, Viking reported that adverse events for oral VK 2735 were classified as mild to moderate.

在100 mg队列中，28天时平均体重减轻6.8%。尽管这些队列中的剂量较高，但研究药物仍然安全且患者耐受性良好。虽然胃肠道副作用是目前可用的肥胖药物的已知并发症，但Viking报道，口服VK 2735的不良事件被归类为轻度至中度。

Viking said weight loss persisted as observed in follow-up visits through day 57. Based on a preliminary evaluation of the trajectory of weight loss at multiple dose levels, the company believes continued treatment beyond four weeks may provide further reductions in weight..

维京说，在第57天的随访中观察到体重持续下降。根据对多剂量水平下体重减轻轨迹的初步评估，该公司认为持续治疗四周以上可能会进一步减轻体重。。

Presentation of these results at Obesity Week included new pharmacokinetic data showing all patients who received the study drug maintained the majority of their weight loss four weeks after receiving their last dose of the drug in the clinical trial. Viking said it believes these results show the injectable drug could be dosed once-monthly as a maintenance treatment. .

在肥胖周上介绍这些结果包括新的药代动力学数据，显示所有接受研究药物的患者在临床试验中接受最后一剂药物四周后仍保持大部分体重减轻。。。

VK 2735 is part of a growing class of drugs that work by mimicking hormones in the gut to spark a range of metabolic effects. Novo Nordisk’s Wegovy targets and activates the GLP-1 receptor. The Viking drug is an agonist of both the GLP-1 and GIP receptors. The preliminary results  are from a placebo-controlled Phase II clinical trial that tested four doses of the Viking drug, administered as a once-weekly injection.

VK 2735是一类越来越多的药物的一部分，这些药物通过模仿肠道中的激素来激发一系列代谢作用。诺和诺德的Wegovy靶向并激活GLP-1受体。维京药物是GLP-1和GIP受体的激动剂。初步结果来自安慰剂对照的II期临床试验，该试验测试了四剂Viking药物，每周一次注射。

The study enrolled 176 adults who are obese or overweight with at least one weight-related co-existing condition. The main goal was to measure the percent change in body weight after 13 weeks..

这项研究招募了176名肥胖或超重的成年人，他们至少有一种与体重相关的共存疾病。主要目标是测量13周后体重的百分比变化。。

Viking said the statistically significant weight loss was observed for all doses starting at week one and continuing throughout the course of the 13-week study. Furthermore, up to 88% of participants in the treatment groups achieved 10% or greater weight loss compared with just 4% of those in the placebo arm.

维京说，从第一周开始，在整个13周的研究过程中，观察到所有剂量的体重都有统计学意义上的显着减轻。此外，高达88%的治疗组参与者体重减轻了10%或更多，而安慰剂组只有4%。

The Viking drug was safe and well tolerated.

维京人的药物安全且耐受性良好。

Condition: Obesity

条件：肥胖

Type: drug

类型：药物